Dubai, United Arab Emirates — The International Society for Stem Cell Application (ISSCA) announces the International Congress in Regenerative Medicine – ISSCA UAE 2026, taking place on June 5–6, 2026, in Dubai, United Arab Emirates. This edition marks ISSCA’s third consecutive year of presence in Dubai, reinforcing the city’s role as a strategic global hub where advanced medical education, regenerative science, and emerging technologies—such as artificial intelligence (AI)—converge.
Over the past three years, ISSCA has established a consistent footprint in the UAE, responding to growing interest from physicians across the Middle East, Europe, Asia, and Africa. The 2026 edition represents a new phase of consolidation and expansion, integrating cutting-edge scientific education with exposure to AI-driven innovation that is increasingly shaping the future of regenerative and precision medicine.
“Dubai has positioned itself at the intersection of healthcare innovation and advanced technology,” said Benito Novas, Founder of ISSCA.
“Our continued presence here reflects not only the city’s global vision, but also ISSCA’s commitment to connecting regenerative medicine with emerging tools such as artificial intelligence, data-driven clinical decision-making, and next-generation medical technologies.”
DubAI as a Strategic Platform for Regenerative Medicine and AI
Dubai’s rapid adoption of AI across healthcare, diagnostics, and personalized medicine has created an ecosystem where innovation moves from concept to implementation at an accelerated pace. For ISSCA, this environment offers a unique opportunity to explore how AI-enhanced analytics, predictive modeling, and clinical optimization tools can support the evolution of regenerative therapies.
ISSCA UAE 2026 will bring together clinicians, researchers, and innovators to examine how regenerative medicine can evolve alongside AI—not as a replacement for clinical judgment, but as a complementary tool to improve precision, safety, and scalability in medical practice.
“Sustaining an international congress in Dubai year after year requires operational excellence and adaptability,” said Yamile Noriega, Director of Operations at ISSCA.
“Dubai’s innovation-driven ecosystem allows ISSCA to deliver a consistently high-level educational experience while engaging with the latest technological advancements influencing modern medicine.”
Advanced Scientific Program with a Forward-Looking Perspective
ISSCA UAE 2026 will feature a comprehensive scientific agenda focused on the most relevant clinical applications of regenerative medicine, including:
- Cellular and regenerative therapies
- Peptide-based clinical strategies
- Exosome science and emerging biologics
- Longevity, metabolic health, and inflammation control
- Musculoskeletal repair and functional restoration
- The growing role of AI in clinical optimization, diagnostics, and personalized treatment planning
The program is designed to help physicians understand not only current best practices, but also how innovation—particularly AI—may influence the future of regenerative medicine.
Beyond Education: Global Collaboration and Innovation Exchange
The Dubai congress extends beyond academic sessions. Curated environments within the event will enable physicians, faculty, and industry leaders to exchange insights on clinical practice, innovation, and technology adoption.
These interactions reinforce ISSCA’s role as a global platform where medical leaders connect, collaborate, and engage with the technologies shaping the next generation of healthcare, including artificial intelligence and data-driven medicine.
A Consolidated Presence with Global Impact
ISSCA’s third consecutive year in Dubai underscores a long-term strategic commitment to the UAE—not simply as a host location, but as a gateway to global medical innovation. As regenerative medicine continues to evolve, Dubai provides the infrastructure, vision, and technological leadership necessary to support high-level education and international collaboration.
ISSCA UAE 2026 reflects the organization’s mission to remain at the forefront of medical progress by aligning regenerative science with the tools that will define the future of healthcare.
Physicians and healthcare professionals interested in attending ISSCA UAE 2026 (June 5–6) can register at:
Early registration benefits include:
- Special Early-Bird pricing
- Priority access to certification programs
- Admission to MedConnect Brasil
- Pre-event educational materials and digital resources
About ISSCA
“The International Society for Stem Cell Application (ISSCA) is a leading organization in the field of regenerative medicine. It is dedicated to advancing the science and practice of stem cell therapy and regenerative medicine through education, certification, research, and training. ISSCA provides certification training in cities worldwide, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty.”
About Global Stem Cells Group
“Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.”
Safe Harbor Statement
Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business, partly based on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
